Resmed Inc. Stock
Resmed Inc. Stock
A loss of -2.410% shows a downward development for Resmed Inc..
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
As a result the target price of 259 € shows a positive potential of 23.22% compared to the current price of 210.2 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | -2.410% | 0.233% | 2.328% | -5.194% | -3.104% | 6.423% | 25.233% |
| Veeva Systems A | -1.600% | -8.836% | -25.783% | -14.106% | -7.849% | 17.178% | -15.425% |
| Thermo Fisher Scientific Inc. | -2.250% | 0.389% | -1.576% | -2.351% | -1.832% | -5.984% | 26.569% |
| Waters Corp. | -2.560% | -2.873% | -1.944% | -10.238% | -7.790% | 1.753% | 64.774% |
Comments
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
